Pfizer: two competitors exited and pricing stabilised
The deflation that defined this industry has stopped in the categories that matter to this company.
Unlock the full report
The locked call and the disclosures stay visible. The research body unlocks with purchase or subscription.
Discussion · 6
This is the second-order point everyone skips. The comp table did more work for me than the narrative did. Where does this break if rates back up another 50bp?
This changed my mind. The distinction between adequate reserves and the earnings path is well made. What is the level where you would walk away?
Good to see an invalidation level actually stated. The cohort split is the detail that everyone leaves out. What does the bear actually have to be right about?
Been on the sidelines on this one. The depreciation schedule really is the whole disagreement. Interested in what the kill switch looks like in practice.
Been long since the last one. Splitting volume from price is what makes this legible. Where does this break if rates back up another 50bp?
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (932)